After 24 weeks of taking tezepelumab, the percentage of participants who had well-controlled asthma was:
- 34.9% of the participants who got tezepelumab through the accessorized pre-filled syringe. This was 38 out of 109 participants.
- 36.2% of the participants who got tezepelumab through the autoinjector. This was 38 out of 105 participants.

What medical problems happened during the study?
This section is a summary of the medical problems the participants had during the study that the study doctors thought might be related to the study drug. These medical problems are called "adverse reactions". An adverse reaction is considered "serious" when it is life-threatening, causes lasting problems, or requires hospital care. These adverse reactions may or may not be caused by the study drug. A lot of research is needed to know whether a drug causes an adverse reaction. These adverse reactions have been, and will continue to be, reviewed together with all of the available data for the study drug.

The websites listed at the end of this summary may have other information about adverse reactions or other medical problems that happened during this study.

Did any adverse reactions happen during this study?
There were 2.8% of participants who had adverse reactions during this study. This was 6 out of 216 participants.
- None of the participants who got tezepelumab through the accessorized pre-filled syringe had an adverse reaction.
- 5.7% of the participants who got tezepelumab through the autoinjector had adverse reactions. This was 6 out of 105 participants.

None of the participants had serious adverse reactions.
None of the participants stopped taking study treatment due to adverse reactions.